FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1786 December 10, 1998 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lai, C.-L. PubMed Citation

To the Editor: Lai et al. (July 9 issue)¹ provide important data on the clinical and virologic efficacy of lamivudine for the treatment of hepatitis B virus (HBV). However, because of the potential for mutations of the gene encoding the RNA-dependent DNA polymerase of HBV, it is very unlikely that a single medication will ever become standard therapy for this infection.

We are particularly concerned about the choice of a once-daily regimen of lamivudine. The anti-HBV activity of lamivudine yielded 50 percent inhibitory concentrations of about 0.01 µM (i.e., values nearly identical to those reported for the human immunodeficiency virus . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.